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ignaling through growth factor receptors controls such
diverse cell functions as proliferation, migration, and
differentiation. A critical question has been how the
activation of these receptors is regulated. Most, if not all, of
the known ligands for these receptors are soluble factors.
However, as matrix components are highly tissue-speciﬁc
and change during development and pathology, it has been
suggested that select growth factor receptors might be stim-
ulated by binding to matrix components. Herein, we de-
scribe a new class of ligand for the epidermal growth factor
(EGF) receptor (EGFR) found within the EGF-like repeats of
tenascin-C, an antiadhesive matrix component present dur-
ing organogenesis, development, and wound repair. Select
EGF-like repeats of tenascin-C elicited mitogenesis and
EGFR autophosphorylation in an EGFR-dependent manner.
Micromolar concentrations of EGF-like repeats induced
EGFR autophosphorylation and activated extracellular sig-
nal–regulated, mitogen-activated protein kinase to levels
S
 
comparable to those induced by subsaturating levels of
known EGFR ligands. EGFR-dependent adhesion was
noted when the ligands were tethered to inert beads, sim-
ulating the physiologically relevant presentation of tena-
scin-C as hexabrachion, and suggesting an increase in
avidity similar to that seen for integrin ligands upon surface
binding. Speciﬁc binding to EGFR was further established
by immunoﬂuorescence detection of EGF-like repeats
bound to cells and cross-linking of EGFR with the repeats.
Both of these interactions were abolished upon competi-
tion by EGF and enhanced by dimerization of the EGF-like
repeat. Such low afﬁnity behavior would be expected for a
matrix-“tethered” ligand; i.e., a ligand which acts from the
matrix, presented continuously to cell surface EGF recep-
tors, because it can neither diffuse away nor be internal-
ized and degraded. These data identify a new class of “in-
soluble” growth factor ligands and a novel mode of
activation for growth factor receptors.
 
Introduction
 
The EGF receptor (EGFR)* transduces signals from the ex-
tracellular milieu to trigger diverse cell functions. EGFR sig-
naling has been shown to play critical roles in organogenesis,
tissue maintenance and repair, and, when dysregulated in can-
cers, to promote tumor progression (Khazaie et al., 1993;
Wells et al., 1998; Wells, 2000). The several known ligands
for EGFR are peptide growth factors that are processed from
membrane-associated propeptides. These ligands can engage
 
and activate EGFR in both their soluble and membrane-
anchored forms (Brachmann et al., 1989; Anklesaria et al.,
1990; Wells et al., 1990) and when chemically tethered to a
substratum (Kuhl and Griffith-Cima, 1996). In addition,
EGFR signaling and mitogenesis can be fully signaled from
plasma membrane–restricted receptors (Wells et al., 1990;
Vieira et al., 1996; Haugh et al., 1999). As internalization of
ligand serves to attenuate signaling (Wells et al., 1990; Reddy
et al., 1996b), presenting an EGFR ligand as part of a larger
extracellular complex would present novel signaling and mod-
ulatory possibilities. It may, for example, serve to coposition
activated integrin and growth factor receptors to modulate in-
tegrin functioning in processes like cell migration. Although
growth factor receptors have been traditionally thought to in-
teract with high avidity to individual ligands, the discoidin
domain receptor recognize and initiate signaling in response
to epitopes in matrix collagen (Shrivastava et al., 1997; Vogel
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et al., 1997). Thus, it has been hypothesized that similar ma-
trix signals may exist for other growth factor receptors.
Several matrix components possess EGF-like repeats, the
functions of which are largely unknown. Two of these com-
ponents have been suggested to initiate signaling through the
EGFR. The EGF-like repeats in laminin and tenascin-C
(hexabrachion) have been shown to modulate cell adhesion
and cell motility (Prieto et al., 1992; Nelson et al., 1995). Ex-
periments have suggested that these repeats may directly trig-
ger EGFR signaling by acting as very low affinity ligands (En-
gel, 1989; Panayotou et al., 1989; Nelson et al., 1995) or
potentiate signaling from soluble EGF (Jones et al., 1997).
However, these previous studies did not directly isolate EGFR
signaling or binding and therefore the exact mechanism of
signaling remains undetermined. Furthermore, low affinity
ligands (dissociation constant kd in the micromolar range at
best) would not be detected by standard binding assays. Low
values of solution phase affinity would be predicted for ma-
trix-embedded EGFR ligands because they effectively act
from two dimensions, constrained at the cell surface. The ef-
fective concentration is increased by being constrained to the
interface between the extracellular matrix and the cell surface.
Further, the tethered ligand receptor complexes are physically
restrained from entering the cell and thus impervious to the
major long-term attenuation mechanism of ligand-dependent
internalization and degradation (Herbst et al., 1994).
We decided to investigate whether the EGF-like repeats in
tenascin-C activate EGFR, as tenascin-C is restricted to sites
of tissue development and regeneration and is up-regulated
in tumor cells, all of which are sites of EGFR functioning
(Erickson, 1993; Chiquet-Ehrismann, 1995). To isolate
EGFR signaling, we used NR6 mouse fibroblasts devoid of
endogenous EGFR (Pruss and Herschman, 1977) that have
been engineered to express various EGFR constructs (Wells,
et al., 1990). We found that select EGF-like repeats of ten-
ascin-C were capable of eliciting mitogenesis in an
EGFR-dependent manner. Furthermore, although EGFR
autophosphorylation was negligible at best, extracellular
signal–regulated kinase (ERK) mitogen-activated protein
(MAP) kinase activation was comparable to subsaturating
levels of known EGFR ligands. These cell responses required
the extracellular ligand-binding motifs of EGFR, suggesting
direct binding. EGFR-dependent adhesion was noted when
the predicted avidity of the EGF-like repeat was increased by
dimerization or polyvalency via tethering the ligands to inert
beads, thereby simulating the physiologically relevant pre-
sentation of tenascin-C as hexabrachion. Immunofluores-
cent imaging further revealed EGFR-dependent binding of
the EGF-like repeats to the cell surface. These bindings were
abolished upon preincubation with EGF ligand. Direct
proof of interaction was demonstrated by cross-linking of
EGFR to the EGF-like repeats of tenascin-C.
 
Results
 
EGF-like repeats of tenascin-C have mitogenic 
activity dependent on functional EGFR
 
The EGF-like repeats of tenascin-C were expressed and pu-
rified as recombinant proteins in 
 
Escherichia coli
 
; this mode
of expression was chosen because bacterial expression results
in fully functional EGF (Reddy et al., 1996a). All 14 repeats
were divided among separate clones containing one, two, or
three contiguous repeats. Each clone was tested for EGFR-
dependent mitogenic activity by a
 
 3
 
H-thymidine incorpora-
tion assay using NR6 fibroblasts transduced to overexpress
either the wild-type (WT) or a kinase-inactive mutant (M)
EGFR (WT NR6 and M NR6, respectively). The EGFR M
mutant contains a methionine substituted for lysine 721,
abolishing the kinase activity of the EGFR and, hence, its
autophosphorylation. Cells were treated with concentrations
of each protein, which varied from 1–4 uM, depending on
the preparation/purification. The two proteins correspond-
ing to EGF-like repeats 1/2 (Ten1/2) and 11/12/13 (Ten11/
12/13), exhibited mitogenic activity on WT NR6 cells at 2
and 4 uM, respectively, but not at 10 and 1% of their initial
concentration (Fig. 1 A). Ten14 (the 14th EGF-like repeat
from the NH
 
2
 
-terminal end) exhibited mitogenic activity at
3 uM (ninefold over uninduced) and slight mitogenic activ-
ity at 0.3 uM (threefold over uninduced), but none at 0.03
uM. Since known soluble EGFR ligands can drive prolifera-
tion at 
 
 
 
0.01 kd, this suggested that we were at the lower
end of effective ligand concentration and below the solution
kd of this matrix-derived ligand (Reddy et al., 1996a). The
mitogenic activity was dependent on functional EGFR, as
no increased incorporation was observed for the M NR6
cells expressing the kinase-inactive EGFR mutant. To ex-
clude the possibility that these repeats might be potentiating
an unknown growth factor signal within the quiescence me-
dia, mitogenesis was repeated in serum-free media for the
Ten14 repeat. Fold induction of thymidine incorporation
over uninduced control in dialyzed serum-free media was
comparable to results obtained with quiescence media (Fig.
1 B). Thus, mitogenic stimulation is an inherent property of
these repeats. The absence of activity from similar concen-
trations of proteins containing repeats 9/10, and of EGF-
like repeats from laminin 
 
 
 
1 chain (data not shown), which
were cloned and purified in parallel and identical manner,
establishes specificity of the observed activity to select EGF-
like repeats.
 
EGF-like repeats of tenascin-C directly activate EGFR
 
The ability of these three repeat proteins to activate the
EGFR was assessed by induction of tyrosine phosphoryla-
tion of the EGFR in treated cells. Activation of the WT
EGFR of WT NR6 cells was induced upon treatment with
each of the three repeat proteins that scored for mitogenesis,
as detected by slightly increased tyrosyl-directed phosphory-
lation (Fig. 2 A). The induced activation required EGFR ki-
nase, because tyrosine phosphorylation of the kinase-inactive
EGFR mutant protein of M NR6 cells was not observed
upon treatment. The degree of EGFR phosporylation by the
EGF-like repeats was seen to be relatively small compared
with EGF or the low-affinity EGF ligand Y13G at concen-
trations approximately kd (
 
 
 
2 nM for EGF; 
 
 
 
0.1 uM for
Y13G); yet it was comparable to the degree of EGFR phos-
phorylation achieved by lower (
 
 
 
0.01 kd), but physiologi-
cally relevant, concentrations of these two ligands (Fig. 3 A).
Both EGF and Y13G elicit maximal stimulation of mito-
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genic response in WT NR6 cells at concentrations of 
 
 
 
0.01
kd (Reddy et al., 1996a). Thus, the activation pattern for
EGFR by the tenascin EGF–like repeats in soluble form is
similar to that for an EGFR ligand at a concentration signif-
icantly below solution kd but significantly above the thresh-
old required to stimulate a mitogenic response.
Because the degree of EGFR phosphorylation is not a sen-
sitive indicator of the degree of mitogenic response, we also
determined whether downstream signaling is initiated. A
crucial pathway for mitogenesis and motility signaled by
EGFR is the one leading to MAP kinase activation. Both
ERK MAP kinases were dually phosphorylated in response
to the tenascin repeats 1/2, 11/12/13, and 14, but not 9/10
(Fig. 2 B). Again, this was noted only in WT NR6, not M
NR6 cells. That the M NR6 cells were competent was dem-
onstrated by exposure to serum inducing both mitogenesis
and ERK/ MAP kinase phosphorylation.
This pattern of relatively small phosphorylation of EGFR
but robust activation of ERK MAP kinases is not unex-
pected if one considers the highly nonlinear effects that re-
sult from differential rates of signal activation and attenua-
tion of molecules activated downstream from EGFR (Bhalla
and Iyengar, 1999). Such nonlinearities can result, for exam-
ple, in persistent activation of MAP kinase or PKC after the
EGF signal is withdrawn and maximal pathway stimulation
over a wide range of concentrations of signaling pathway
components (Bhalla and Iyengar, 1999). The EGFR is sub-
ject to multiple signal attentuation mechanisms, including
rapid dephosphorylation and internalization (Welsh et al.,
1991; Countaway et al., 1992; Hernandez-Sotomayor et al.,
1993), but at the same time is associated with a prolonged
activation or slower deactivation of downstream signals,
such as persistence of grb2–SOS interactions (Waters et al.,
1996). The observed EGFR activation pattern would be ex-
pected for either a ligand at concentrations significantly be-
low kd or a low affinity ligand with a high off-rate. This was
tested with both a high affinity ligand (EGF, kd 
 
 
 
2 nM)
and a lower affinity ligand (Y13G-EGF, kd 
 
 
 
100 nM; 41;
Fig. 3 B). As observed, EGFR autophosphorylation was
barely demonstrable at 0.1 kd for both these ligands. Nota-
bly, though, dually phosphorylated ERK MAP kinase could
be detected at even lower concentrations: 0.01 kd for both
ligands, and both ligands stimulated maximal MAP kinase
phosphorylation at 0.01 kd. It was at approximately this
level of fractional kd that Ten14 induced dually phosphory-
lated ERK MAP kinase (Fig. 3 C).
These data suggest that EGFR phosphorylation would be
enhanced by limiting attenuation or increasing ligand acces-
sibility. We used sodium vanadate to block receptor dephos-
phorylation, as this is the most rapid attenuation event
(Hernandez-Sotomayor et al., 1993; Fig. 3 D). Treatment
with this generalized tyrosine phosphatase inhibitor in-
creased EGFR phosphotyrosine content after exposure to
Ten14; similar vanadate-increased EGFR phosphorylation
was noted in response to low levels of EGF (0.01 nM), dem-
onstrating fidelity of the assay. To increase signaling persis-
tence and/or ligand accessibility, we tethered EGFR ligands
via the NH
 
2
 
-termini to 
 
 
 
1-um diameter latex beads using
20 nm polyethylene oxide (PEO) flexible spacer chains to
ensure ligand accessibility. This represents an initial attempt
to present low affinity ligands in a context that mirrors
ligands constrained within the extracellular matrix (Kuhl
and Griffith-Cima, 1996). When the tenascin 14 repeat was
covalently tethered to these beads, a significantly higher level
of tyrosyl-phosphorylation was observed over that obtained
with soluble, monomeric ten14 (Fig. 3 E). It was noted that
EGFR phosphorylation increased with time exposed to the
tenascin-tethered beads; however, it remains to be deter-
mined whether this is due to slow diffusion and settling of
beads or reflects a situation akin to eph receptor activation
(Davis et al., 1994). These data support the finding that se-
lect tenascin EGF–like repeats directly activate the EGF re-
ceptor from an insoluble presentation mode. Furthermore,
the initial findings with these insoluble ligand complexes
strongly suggest that manner of ligand presentation alters
the balance between signaling and attenuation.
Figure 1. Tenascin-C EGF–like repeats stimulate cell mitogenesis. (A) WT (black) or M (open) NR6 cells were exposed to the EGF-like re-
peat proteins, and 
3H-thymidine incorporation was assessed. EGF (1 nM) and serum (1%) were used as positive controls (for WT and M NR6 
cells, respectively). The EGF-like repeat proteins were used at the following concentrations: left bars are 2 uM for 1/2; 1 uM for 9/10; 4 uM for 
11/12/13; and 3 uM for 14, and at 10 and 1% of that level for each concentration (middle and right bars). (B) Mitogenesis assay performed in 
serum-free media on WT NR6 cells with decreasing concentrations of Ten14 as described. No tx designates cells not exposed to ligand. Val-
ues are the mean  SD (performed in triplicate) for one experiment representative of three experiments.
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The MAP kinase signaling pathway is activated 
by the EGF-like repeats of tenascin-C through 
their direct activation of EGFR
 
That EGFR kinase activity is required for downstream cell
responses was corroborated directly by inhibiting EGFR us-
ing the pharmacological agent PD153035. This selective in-
hibitor of EGFR kinase blocked ERK MAP kinase activa-
tion by the tenascin EGF–like repeats (Fig. 4 A).
The foregoing results may be due to the tenascin repeats
interacting with an unknown receptor but transmitting sig-
nal through an intact EGFR kinase, as has been reported re-
cently for G protein–linked receptors (Daub et al., 1996),
integrins (Li et al., 1999), and growth hormone receptor
(Yamauchi et al., 1997). To probe this unlikely possibility,
we blocked the external binding site of known EGFR
ligands using a nonactivating antibody (clone 528; Sunada
et al., 1986). The extracellular domain antibody inhibited
the induced MAP kinase activation (Fig. 4 B), indicating
that activation of the EGFR by tenascin-C EGF–like repeat
occurs through the ligand binding, extracellular domain of
the EGFR. However, it is still possible that the signals occur
by a receptor cascade in which the unknown receptor causes
release of membrane-anchored EGFR ligands that then act
in autocrine fashion, as has been shown for G protein–cou-
pled receptors (Prenzel et al., 1999). This is unlikely, as
NR6 cells are not known to produce significant levels of
EGFR ligands. However, we challenged B82 cells that have
been shown not to express any of the known EGFR ligands
(Oehrman et al., 1998) with the tenascin 14 fragment (Fig.
4 C). The tenascin 14 fragment activated ERK MAP kinase
similarly to what had been noted in WT NR6 cells.
 
Tenascin EGF–like repeats directly bind to EGFR
 
Final proof that these EGF-like repeats act as novel direct
EGFR ligands, however, requires a visualization of EGFR-
dependent binding and/or a demonstration of an interaction
with EGFR. In direct binding assays, we were unable to de-
tect specific binding to the EGFR by the EGF-like repeat
proteins at micromolar concentration (data not shown).
This indicates that the ligand is quite low affinity (
 
 
 
10 uM)
when compared with prototypical growth factor ligands for
EGFR (in the low nanomolar range). This proposed low so-
lution affinity of the tenascin 14 repeats appears to be com-
mensurate with the solution affinities for integrin ligands,
which are in the micromolar range for fibronectin (Akiyama
and Yamada, 1985) and the millimolar range for linear argi-
nine–glycine–aspartic acid peptides (Pierschbacher and
Ruoslahti, 1987). Since specific binding to these integrin
ligands can be readily detected by presenting the ligands
from the solid phase (i.e., bound to beads or the substrate;
Pierschbacher and Ruoslahti, 1984) in a relatively normal
physiological manner, we reasoned that specific binding to
the tenascin 14 repeats might also be detected by presenting
the repeats in a method that resembles their presentation in
ECM. We generated 
 
 
 
1-um diameter beads that presented
a high surface density of ligand (either tenascin 14 or EGF).
Beads presenting EGF or the tenascin 14 fragment exhibited
specific adhesion to WT NR6 cells compared with control
beads (Fig. 5). That this occurred via EGFR is demonstrated
by blocking of binding by anti-EGFR antibodies (number of
bound beads were reduced by 
 
 
 
90% in each of three in-
dependent experiments). There was negligible binding to
M721 NR6 cells, which are devoid of EGFR.
Direct interaction of the EGF-like repeats with EGFR
should be enhanced by increasing the valency of the ligand,
with even dimerization sufficient to achieve a log-greater
avidity (Mammen et al., 1998). Ligands were predimerized
with an antibody to the poly-His tag at the NH
 
2 
 
terminus of
the expressed repeats. The binding of these ligands to WT
NR6 cells was visualized by indirect immunofluorescence
(Fig. 6). As a positive control, murine EGF (mEGF-His6)
was cloned and purified in a similar manner as the tenascin
EGF–like repeats. Ten14 dimers bound at a level signifi-
cantly greater than antibody alone. Most importantly, this
Figure 2. Tenascin EGF–like repeats activate the EGFR kinase cas-
cade. WT (top) and M (bottom) NR6 cells were treated with EGF-
like repeat proteins and activation of EGFR signaling was assessed. 
(A) EGFR autophosphorylation was determined by antiphosphoty-
rosine immunoblotting of immunoprecipitated EGFR after treatment 
with EGF or EGF-like repeats 1/2 (5 uM), 11/12/13 (1 uM), or 14 (6 
uM). Immunoblotting with an antibody to EGFR demonstrated equal 
loading (data not shown). (B) ERK MAP kinase activation was as-
sessed by immunoblotting for dually phosphorylated p44/p42 ERK, 
indicative of activated ERK. The cells were treated with various con-
centrations of the EGF-like repeats (5 uM for 1/2; 2 uM for 9/10; 1 
uM for 11/12/13; and 6 uM for 14) and at 50 and 10% of those lev-
els. EGF and serum were used as positive controls (for WT and M 
NR6 cells, respectively). Numbers below a lane represent relative 
values of intensity for pEGFR or p42 in each lane for that experi-
ment as determined by densitometry. In both panels, an experiment 
representative of at least three determinations are shown.
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binding, and that of mEGF-His6, was competed by 100 nM
EGF that did not present the poly-His tag. Interestingly,
Ten14 that was not predimerized also demonstrated statisti-
cally significant cell association, though at a slightly lower
level than the predimerized Ten14. These data, including
the bead-binding study, strongly support the model of low
affinity ligands interacting with the EGFR.
The final demonstration would be to biochemically de-
tect an association between EGFR and Ten14. To confirm
the immunofluorescence of Ten14 binding to EGFR, we
cross-linked the ligands to their receptors and examined im-
munoprecipitates of the poly-His tags. Upon poly-His
immunoprecipitation, we detected EGFR in cells dithio-
bis(succinimidyl propionate) cross-linked in the presence of
either mEGF-His6 or Ten14 (Fig. 7 A). This interaction was
not noted in cells competitively treated with 100 nM unla-
beled EGF. Diluent (notx) or just secondary antibody (IgG)
alone did not identify any cell surface receptor. Further-
more, we assessed specificity by probing for another cell sur-
face receptor, the insulin receptor (Fig. 7 B); we could not
detect any interaction between Ten14 or mEGF-His6 and
this receptor, further establishing the fact that binding is
specific for EGFR. That Ten14 coprecipitated at least simi-
lar levels of EGFR, as did mEGF-His6, is not unexpected.
The extended period of cross-linking would minimize the
effects of the rapid off-rate predicted for Ten14 and thus
“drive” the binding towards completion. The slight retarda-
tion of migration for EGFR noted is also not unexpected for
Figure 3. Differential detection of acti-
vation of the EGFR kinase cascade. (A 
and B) WT NR6 cells were treated for 5 
min with decreasing concentrations of a 
high affinity (EGF, kd  2 nM; left) or 
lower affinity (Y13G-EGF, kd  100 nM; 
right; Reddy et al., 1996a) EGFR ligand. 
Activation status of EGFR was deter-
mined by immunoblotting with the PY20 
antiphosphotyrosine antibody of 175 kD 
(A), and ERK MAP kinase activation was 
assessed by immunoblotting for dually 
phosphorylated p44/p42 ERK, indica-
tive of activated ERK (B). no tx designates cells not exposed to 
ligand. (C) WT NR6 cells were treated as in B with various concen-
trations of EGF or 2 uM tenascin 14 fragment in quiescence media 
or serum-free media. The two different concentrations of Ten14 are 
from different preparations. ERK MAP kinase activation was as-
sessed as in B. In A–C, concentration in nM of EGFR ligand used for 
treatment is indicated. (D and E) Augmentation of EGFR phosphory-
lation by decreased attenuation mechanisms in WT NR6 cells. (D) 
WT NR6 cells were treated for 30 min with EGF (0.1 or 0.01 nM) or 
tenascin 14 fragment (2 uM) in the presence of 0.1 mM sodium van-
adate; EGFR activation status was determined as in A. (E) EGFR 
ligands were tethered to PEO latexes and tested for the ability to in-
duce EGFR phosphorylation. WT NR6 cells were exposed to EGF (5 
min at 10 or 1 nM), bead complexes containing tenascin 14 frag-
ments (30, 120, and 240 min), bead complexes containing EGF (30 
min of 20- and 5-ul beads), or control beads (30 min); EGFR activa-
tion status was determined as in A. Numbers below a lane represent 
relative values of intensity for pEGFR or p42 in each lane for that ex-
periment as determined by densitometry. In all panels a representa-
tive experiment is shown of at least three determinations.
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chemically cross-linked proteins. In summation, these data
demonstrate that Ten14 directly binds to EGFR.
 
Discussion
 
These data indicate that select EGF-like repeats may act as
low affinity ligands of the EGFR. We could detect binding
to EGFR upon tethering tenascin fragments to a bead to
present a multivalent ligand in a manner similar to a matrix-
embedded situation, a situation which is predicted of low af-
finity ligands and has been observed for integrin ligands
(Juliano et al., 1993; Maheshwari et al., 2000), and by in-
creasing the valency by dimerization with antibody. Most
conclusively, we could cross-link an EGF-like repeat to
EGFR. It is not surprising that these repeats are of low affin-
ity, since they lack the second loop of the EGF structure that
is required for high affinity interaction with the receptor
(Montelione et al., 1987; Engler et al., 1988; Tadaki and
Niyogi, 1993). Still, these tenascin EGF–like repeats may
represent a new class of matrix-encoded ligands for growth
factor receptors (“matrikines”), further supporting the opin-
ion that “there is little or no justification for drawing a dis-
tinction between adhesion receptors and receptors for solu-
ble ligands...indeed, many “soluble” growth factors often do
not function as truly soluble molecules” (Hynes, 1999).
 
It has been suggested previously that EGF-like repeats po-
tentiate signaling from growth factor receptors through the
activation of integrins and other signaling transducers (Jones
et al., 1997). The entire matrix protein tenascin-C presents
numerous interactive and signaling elements. However, we
do not feel that this indirect action explains the signaling
from the EGF-like repeats. First, these repeats activated bio-
chemical and biological responses in the absence of soluble
factors (i.e., serum-free conditions) dependent on binding to
a signaling competent EGFR (Figs. 1–4). These data do not
exclude the possibility of signaling through release of mem-
brane-associated EGFR ligands (Daub et al., 1996; Prenzel
et al., 1999). This scenario is countered by the second set
of data, those demonstrating direct interactions between
Ten14 and EGFR (Figs. 5–7). We could demonstrate
EGFR-specific bead binding and Ten14 binding and cross-
linking. These interactions were prevented by anti-EGFR
antibodies and competed by unlabeled EGF, demonstrating
that they occurred through the ligand binding site of EGFR.
In short, we have provided definitive evidence for direct
binding of EGFR by EGF-like repeats.
The physiological role of such a low affinity ligand re-
mains an open question. One of the main attenuation mech-
anisms necessary to prevent excessive signaling is EGFR in-
ternalization and subsequent degradation of receptor and/or
ligand (Welsh et al., 1991; Reddy et al., 1996b). For a ligand
that is embedded in the extracellular matrix, such internal-
ization would be physically limited and constantly represent
itself even after dissociation due to its physical proximity to
the cell surface. A matrix-embedded ligand with high affinity
would lead to continuous, strong signaling through EGFR;
this has been shown to lead to cellular transformation (Di-
Fiore et al., 1987; Wells et al., 1990). In contrast, a ligand
with low affinity (fast off rate; Ebner and Derynck, 1991)
would result in ligand decoupling from receptor, allowing
dephosphorylation and other mechanisms (Welsh et al.,
1991; Countaway et al., 1992; Hernandez-Sotomayor et al.,
1993) to function more efficiently at attenuating signaling.
Tenascin-C is an excellent candidate to present such acti-
vators of a receptor that can stimulate both cell proliferation
and migration. Tenascin-C is expressed, by and large, only
during periods of organogenesis and remodeling, such as the
fetal/neonatal growth period and during wound repair, and
is expressed as a hexamer allowing for physiological presen-
tation of multiple potential matricrine ligands (Schalkwijk et
al., 1991; Whitby et al., 1991; Erickson, 1993; Chiquet-
Ehrismann, 1995). During these events EGFR signaling is
required both for proliferation and migration of the cells
(Ashcroft et al., 1995; Miettinen et al., 1995; Sibilia and
Wagner, 1995; Threadgill et al., 1995; Xie et al., 1998; Kim
et al., 1999). In support of such a model, we have found that
NR6 fibroblasts expressing motility competent WT EGFR
(8) present greater transmigration of the human extracellular
matrix Amgel than NR6 cells expressing the motility-defi-
cient c’973 EGFR (26.8 
 
  
 
0.2% vs. 9.6 
 
 
 
 0.3% of the in-
vasiveness of highly invasive HT1080 fibrosarcoma cells;
 
P 
 
 
 
 0.01). This result is similar to transmigration actuated by
EGFR triggered by ligand derived either from autocrine sig-
naling (Xie et al., 1995) or the extracellular milieu (Chakra-
barty et al., 1995; Kassis et al., 1999). This is intriguing as
Figure 4. Inhibition of EGFR activation prevents signaling from 
EGF-like repeats. (A) WT NR6 cells were treated with the tenascin 
EGF–like repeats at concentrations that activate ERK MAP kinase (5 
uM for 1/2; 1 uM for 11/12/13; and 6 uM for 14). The cells were 
treated with the EGF-like repeat proteins in the absence ( ) or pres-
ence ( ) of the EGFR-specific pharmacologic inhibitor PD153035. 
no tx represents no ligand. (B) WT NR6 cells were treated with 
Ten14 (1 uM) or EGF (0.01 nM) in the presence ( ) or absence ( ) 
of an antibody specific for the extracellular domain of EGFR (Clone 
528; Calbiochem) under serum-free conditions. (C) B82 cells ex-
pressing WT EGFR were challenged with tenascin 14 repeats (2 uM) 
under serum-free conditions. Numbers below a lane represent rela-
tive values of intensity for p42 in each lane for that experiment as 
determined by densitometry. Shown are one of three experiments.
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Figure 5. Beads presenting tethered
tenascin 14 fragments bind to EGFR. 
WT NR6 cells were treated for 4 h at 
37 C with beads tethered with either
tenascin 14 or EGF or control beads. 
Cells were washed three times with iced 
PBS and visualized by phase-contrast 
microscopy (top). In parallel, cells were 
treated with 5 ug/ml anti-EGFR antibody 
(clone 528; Sunada et al., 1986; Turner 
et al., 1996) for 15 min before addition 
of beads and continuing throughout the 
4 h (bottom). Beads appear as bright, re-
fractile, and translucent spheres mainly 
above the plane of the cells. Shown is 
one of three experiments.
Figure 6. Tenascin 14 binds to EGFR-
expressing WT NR6 cells. (A) WT NR6 
cells were quiesced for 24 h and ex-
posed to various concentrations of mo-
nomeric or dimerized ligand to visualize 
binding to EGFR. Ten14 and mEGF-His6 
expressed from the same vector 
(pRSETA; Invitrogen) as Ten14 were in-
cubated overnight for dimerization with 
monoclonal anti-HisG (Invitrogen) anti-
body that recognized the NH2-terminal 
poly His epitope of mEGF-His6 and 
Ten14. This was at concentrations of 50 
nM for mEGF-His6 and 25 nM for
monoclonal anti-HisG antibody and
2 uM Ten14 with 0.63 uM of the anti-
body (Ab) to increase affinity to receptor. 
Ligands were incubated for 10 min at room temperature before fixation. 1:500 of goat anti–mouse antibody conjugated to Oregon green was 
used as secondary antibody before visualizing by fluorescence microscopy and captured at a constant exposure by a SPOT II CCD camera. a, 
mEGF-His6 (50 nM); b, mEGF-His6 (50 nM) dimerized with primary antibody (25 nM); c, cells were preincubated with EGF (100 nM) for 5 
min to compete for EGFR with mEGF-His6 (50 nM) dimerized with antibody (25 nM); d, Ten14 (2 uM); e, Ten14 (2 uM) dimerized with pri-
mary antibody(0.63 uM); f, cells preincubated with EGF (100 nM) for 5 min with Ten14 (2 uM) preincubated with 0.63 uM antibody subse-
quently added. (B) Each cell in four randomly selected fields were outlined and measured for luminosity as compared with background. The 
data are the mean  SE of an average of  25 cells per experimental condition. Statistical analyses were performed via Student’s t test. Double 
asterisk represents P   0.01. Shown is one representative of two sets of experiments.
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NR6 cells do not produce known EGFR ligands, and Am-
gel, derived from human amniotic membranes (Siegal et al.,
1993), does not contain detectable levels of EGF, TGF-
 
 
 
,
 
 
 
or
other soluble EGFR ligands, but does contain appreciable
levels of tenascin (75 mg/ml out of 
 
 
 
1,300 mg/ml proteina-
ceous material). Thus, low affinity ligands encrypted within
matrix components might represent a new mode of modula-
tion of cellular responses by matrix acting directly through
growth factor receptors.
 
Materials and methods
 
Cell lines and plasmids
 
The establishment and maintenance of the WT and M NR6 cell lines have
been described previously (Wells et al., 1990; Chen et al., 1994). In brief,
cells were grown in MEM with 7.5% fetal calf serum and 350 ug/ml G418.
Cells were quiesced in MEM containing 1% dialyzed fetal calf serum. Fail-
ure to adequately quiesce the cells results in higher background phosphor-
ylation of EGFR and ERK even in the absence of exogenous added EGFR
ligand. The percentage of dialyzed serum and length of time of the quies-
cence before testing must be empirically determined for each lot of dia-
lyzed serum. For the NR6 cells and our lots of serum, 24 h of quiescence
was sufficient. Tenascin-C cDNA was generated from human placental
RNA by reverse transcriptase PCR using tenascin-C–specific primers (cgcg-
gatccggccccaactgctctgagc and ccggaattcagacacctctgagcagtc), and ligated
into pTrc-His-A (Invitrogen) to yield plasmid pTrc-ten. DNAs coding for
specific EGF-like repeat regions within tenascin-C were generated from the
pTrc-ten template by PCR and ligated into pRSET-A (Invitrogen) to yield
plasmids pTen-1/2, -9/10, -11/12/13, and -14 with the numbers corre-
sponding to the order with which each repeat occurs within tenascin C.
Sequences of primer pairs used in the PCR were cgcggatccggccccaact-
gctctgagc and ccggaattcgatttcacggctgcagtc for pTen-1/2; cgcggatccagc-
cagctacggtgc and ccggaattcttggcgatcccggcag for pTen-9/10; cgcggatcccgg-
gatcgccaatgc and ccggaattcggagtgctggccacag for pTen-11/12/13; and
cgcggatccggccagcactcctgc and ccggaattcagacacctctgagcagtc for pTen-14.
mEGF-His6 was similarly cloned to serve as a control. These clonings
yielded the EGF-like repeats and mEGF preceded by poly-His.
 
Expression and purification of EGF-like repeat proteins
 
Midlog phase cultures of 
 
Escherichia coli
 
 strain BL21/DE3/pLys-S (Strat-
agene) transformed with the individual expression plasmids were induced
for recombinant protein expression with 1 mM isopropyl-b-D-thiogalacto-
pyranoside for 4 h at 37
 
 
 
C. Bacteria were harvested by centrifugation for 10
min at 5,000 
 
g
 
 at 4
 
 
 
C, and bacterial lysates were prepared by extraction
with 0.02 culture volumes of B-PER detergent (Pierce Chemical Co.). Re-
combinant proteins were purified from bacterial lysates by nickel-agarose
chromatography with imidazole elution. Purified protein was dialyzed
against PBS, 0.25 mM 2-mercaptoethanol for 24 h at room temperature.
 
Mitogenesis assay
 
Cells were quiesced for 24 h under normal growth conditions in starvation
medium (serum-free growth medium supplemented with 1% dialyzed fetal
calf serum). The ligand-induced 
 
3
 
H-thymidine incorporation assay has
been described previously (Chen et al., 1996). In brief, cells were exposed
to EGF (1 nM), serum (1%), or various concentrations of EGF-like repeat
proteins for 24 h. 
 
3
 
H-thymidine was added to the cells for the last 8 h to
determine stimulation of proliferation.
 
Phosphorylation assays
 
For assaying EGFR activation, quiesced cells were treated with ligand for 5
min in quiescence medium (for the experiments described in Fig. 3 D only,
the medium was supplemented with 0.1 mM sodium vanadate during this
time period and treated for 30 min). When indicated in the figure legends,
after cells were quiesced the experiment was performed under serum-free
conditions; this further reduces background phosphorylation of ERK. De-
tergent lysates were immunoprecipitated at 4
 
 
 
C with anti-EGFR antibody
(Ab-1; Oncogene Research Products) bound to protein A–conjugated aga-
rose (GIBCO BRL). Immunoprecipitated EGFR was analyzed for tyrosine
phosphorylation by immunoblotting using antiphopshotyrosine antibody
(PY20; Transduction Laboratories). For assessing MAP kinase activation,
quiesced cells were treated with ligand for 5 min in the presence or ab-
sence of anti-EGFR Ab-1 (4 ug/ml; Calbiochem) or PD153035 (1 uM).
Whole cell lysates were analyzed for dually-phosphorylated ERK MAP ki-
nase by immunoblotting using antiphospho-MAP kinase antibody (New
England Biolabs, Inc.). Equal loading was assured using the pan-erk anti-
body. Relative densitometric values were derived with the NIH Image
shareware and Adobe Photoshop
 
®
 
 software.
 
Tethered ligands
 
Tenascin 14 fragments and EGF were covalently tethered to surfaces to
present the ligands in a manner analogous to physiological presentation of
matrix-associated tenascin. Poly(methyl methacrylate) latex beads were
synthesized by dispersion polymerization using an amphiphilic comb co-
polymer stabilizer, following a procedure adapted from (Banerjee et al.,
2000). A comb stabilizer comprised of methylmethacrylate, polyethylene
glycol methacrylate (Mn 
 
 
 
 526 g/mol), and methoxypolyethylene glycol
methacrylate (Mn 
 
 
 
 425 g/mol) in a weight ratio of 30:10:10 was synthe-
sized by free radical polymerization using AIBN as initiator. The hydroxy-
terminated polyethylene glycol side chains were subsequently carbox-
ylated by refluxing 16 g of comb with 10 g succinic anhydride, and 0.15
ml N-methyl imidazole in 300 ml of dichloroethane overnight at 80
 
 
 
C. The
carboxylated product was precipitated and washed with acidified water.
Polyethylene methylmethacrylate latexes were synthesized by the addition
of 9 ml methylmethacrylate, 1.25 g of carboxylated comb stabilizer, 1.2 ml
vinyl methacrylate cross-linking agent, and 0.50 g of ammonium persulfate
initiator to 45 ml of 70:30 (vol/vol) methanol/water. The reaction pro-
ceeded at 50
 
 
 
C for 3 h, resulting in a highly stable dispersion of micron-
sized polyethylene methylmethacrylate latex beads, each coated by comb
polymers that situate and become grafted at the water/bead interface. The
carboxylated latex suspension was purified by repeated centrifugation and
redispersion, before peptide coupling.
The NH
 
2
 
-terminal amine groups of EGF and tenascin 14 fragments were
used to covalently link the peptides to ends of the PEO chains emanating
from the surface of the latex beads. Beads were resuspended in dry ethanol
with 20 mg/mL sulfo-NHS (Pierce Chemical Co.) and 1-ethyl-3-(3-dimeth-
ylaminopropyl)carbodiimide hydrochloride (Pierce Chemical Co.) and ac-
tivated at room temperature for 3 h, then centrifuged to remove superna-
tant and resuspended in ethanol for a total of three washes. Beads were
washed a final time in 100 mM phosphate buffer, pH 7, and resuspended
in 5 ug/mL mouse EGF (Collaborative Biomedical), tenascin 14 fragment,
or buffer alone in 100 mM phosphate buffer, pH 7. The coupling reaction
was allowed to proceed for 24 h at 4
 
 
 
C. Unreacted peptide was removed
and residual NHS reactivity blocked by washing three times in 100 mM
tris buffer, pH 7. The beads were then washed once with sterile PBS before
addition to cells.
Figure 7. Tenascin 14 can be cross-linked to EGFR. Ten14 (2 uM) 
and mEGF (mEGF-His6; 10 nM) were bound and chemically cross-
linked to quiesced WT NR6 fibroblasts and immunoprecipitated 
from ensuing lysates with anti-HisG. Presence of EGFR (A) or insulin 
receptor   chain was assessed by immunoblotting with respective 
antibodies. In lanes 1 and 2, cells were preincubated with 100 nM 
EGF for 5 min and throughout cross-linking as a competitive ligand. 
In lane 5, cells were exposed to and cross-linked with antibody 
alone and lysate was immunoprecipitated. From left to right: 1, EGF/
mEGF-His6 (pretreatment with EGF and addition of mEGF-His6 
ligand); 2, EGF/Ten14 (pretreatment with EGF and addition of 
Ten14 ligand); 3, mEGF-His6 (10 nM); 4, Ten14 (2 uM); 5, IgG (anti-
HisG antibody); 6, No tx (no treatment with ligand); and 7, cell ly-
sate (WT NR6 lysate). Shown is a representative of two experiments. 
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Immunofluorescence
 
WT NR6 cells were quiesced at 50% confluency. Mouse anti-HisG anti-
body (Invitrogen) was incubated 24 h at 4
 
 
 
C with Ten14 or mEGF-His6 for
dimerization. After quiescence, ligand, either without antibody or anti-
body-ligand mix, was added to cells in serum-free media and incubated
for 10 min at room temperature. 100 nM EGF served as a competitor and
was added 5 min before the Ten14 or mEGF-His6. Cells were fixed with
3% formaldehyde for 15 min at room temperature, washed three times
with PBS and incubated in 1% BSA for 30 min. Cells that were exposed to
ligand alone were washed twice with PBS and incubated with mouse anti-
HisG antibody (Invitrogen; 1:1000) for 30 min at 37
 
 
 
C. Cells were washed
five times with PBS and secondary goat anti–mouse conjugated to Oregon
green (Molecular Probes; 1:1,000) was added at 37
 
 
 
C for 30 min. Cells
were once again washed three times, mounted, and viewed.
 
Immunoprecipitation
 
WT NR6 cells were quiesced at 80% confluency. Cells were washed once
with PBS. 100 nM EGF served as a competitor and was added 5 min before
the Ten14 or mEGF-His6. Cells were than washed with PBS and incubated
with ligands Ten14 (2 uM) or mEGF-His6 (10 nM) in PBS for 5 min at room
temperature. In parallel, cells were incubated with just PBS (no tx) or with
monoclonal anti-HisG (0.01 uM) in PBS. Dithiobis(succinimidyl propi-
onate) (Pierce Chemical Co.) was added to the solution and the cells were
placed at 4
 
 
 
C for 30 min. Cells were than washed with 0.2% glycine solu-
tion in PBS twice and incubated with 0.2% glycine in PBS for 5 min at 4
 
 
 
C
followed by a final wash with 0.2% glycine in PBS once again. Cells were
lysed with RIPA lysis buffer with PMSF, aprotinin, and leupeptin as pro-
tease inhibitors. 30 ul of protein G agarose beads (GIBCO BRL) and mouse
anti-HisG (Invitrogen; final concentration, 0.01 uM) was added to the ly-
sate and incubated overnight. Beads were washed for a total of five times.
Lysates were separated by SDS-PAGE with 2-mercaptoethanol (to cleave
the cross-linker), transferred, and immunoblotted. The upper half of the
membrane was probed with a monoclonal anti-EGFR (Zymed Laborato-
ries; 1:500) and the bottom for polyclonal antiinsulin receptor 
 
 
 
-subunit
(Transduction Laboratories; 1:1,000).
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